Maintain back-up drug candidate oxaboroles to replace the drug candidate acoziborole, if needed
current phase of drug development
updated 29 Feb 2020
Extensive pharmacokinetic profiling of possible oxaborole compounds led to the selection of SCYX-1608210 and SCYX‑1330682, which demonstrated cure in the stage 2 mouse model of HAT, as a backup for acoziborole (SCYX-7158) in case of need. Given the current success of other projects for HAT, further development was put on hold in 2013 and will only recommence should problems be encountered with acoziborole (SCYX-7158) in clinical development.
Get our latest news, personal stories, research articles, and job opportunities.